161 related articles for article (PubMed ID: 34179409)
1. Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma.
Halpin SN; Konomos M; Jowers I
J Patient Exp; 2021; 8():2374373521998864. PubMed ID: 34179409
[TBL] [Abstract][Full Text] [Related]
2. The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study.
Camilleri M; Bekris G; Sidhu G; Buck C; Elsden E; McCourt O; Horder J; Newrick F; Lecat C; Sive J; Papanikolaou X; Popat R; Lee L; Xu K; Kyriakou C; Rabin N; Yong K; Fisher A
Support Care Cancer; 2022 Sep; 30(9):7469-7479. PubMed ID: 35657402
[TBL] [Abstract][Full Text] [Related]
3. An Iterative Formative Evaluation of Medical Education for Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant.
Halpin SN; Konomos M
J Cancer Educ; 2022 Jun; 37(3):779-787. PubMed ID: 32978725
[TBL] [Abstract][Full Text] [Related]
4. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
[TBL] [Abstract][Full Text] [Related]
5. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
6. Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma.
Liu J; Li J; Huang B; Zheng D; Chen M; Zhou Z; Xu D; Zou W
Chin J Cancer Res; 2013 Apr; 25(2):166-74. PubMed ID: 23592897
[TBL] [Abstract][Full Text] [Related]
7. Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.
Yadav N; Mirgh SP; Aggarwal M; Agrawal N; Mehta P; Khushoo V; Kapoor J; Bhatia N; Agrawal P; Ahmed R; Bhurani D
Indian J Cancer; 2023; 60(3):316-324. PubMed ID: 37787191
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
[TBL] [Abstract][Full Text] [Related]
9. The role of tandem stem cell transplantation for multiple myeloma patients.
Martino M; Recchia AG; Fedele R; Neri S; Vincelli ID; Moscato T; Gentile M; Morabito F
Expert Opin Biol Ther; 2016; 16(4):515-34. PubMed ID: 26698133
[TBL] [Abstract][Full Text] [Related]
10. Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population.
Cherniawsky HM; AlAhwal H; Mourad YA; Forrest D; Gerrie A; Kuchenbauer F; Nantel SH; Narayanan S; Nevill T; Power M; Sanford D; Toze C; White J; Escano L; Sutherland H; Song K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):476-482. PubMed ID: 33814336
[TBL] [Abstract][Full Text] [Related]
11. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
[TBL] [Abstract][Full Text] [Related]
13. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
[TBL] [Abstract][Full Text] [Related]
14. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang EC; Muffly LS; Shiraz P; Shizuru JA; Johnston L; Arai S; Frank MJ; Weng WK; Lowsky R; Rezvani A; Meyer EH; Negrin R; Miklos DB; Sidana S
Transplant Cell Ther; 2021 May; 27(5):405.e1-405.e6. PubMed ID: 33775587
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
[TBL] [Abstract][Full Text] [Related]
16. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
17. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
Marchesi F; Mengarelli A; Giannotti F; Tendas A; Anaclerico B; Porrini R; Picardi A; Cerchiara E; Dentamaro T; Chierichini A; Romeo A; Cudillo L; Montefusco E; Tirindelli MC; De Fabritiis P; Annino L; Petti MC; Monarca B; Arcese W; Avvisati G;
Transpl Infect Dis; 2014 Feb; 16(1):158-64. PubMed ID: 24215479
[TBL] [Abstract][Full Text] [Related]
18. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
19. Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective.
Hansen DK; Bixby T; Fixler K; Shea L; Brittle C; Brunisholz K; Liu YH; Huo JS
J Patient Exp; 2023; 10():23743735231202733. PubMed ID: 37766811
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.
Kansagra A; Gonsalves WI; Gertz MA; Buadi FK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Kapoor P; Muchtar E; Kourelis TV; Warsame R; Leung N; Zeldenrust SR; Lust JA; Rajkumar SV; Kyle RA; Hogan W; Kumar SK
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2127-2132. PubMed ID: 29656139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
